ES2400107T3 - IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado - Google Patents

IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado Download PDF

Info

Publication number
ES2400107T3
ES2400107T3 ES08840928T ES08840928T ES2400107T3 ES 2400107 T3 ES2400107 T3 ES 2400107T3 ES 08840928 T ES08840928 T ES 08840928T ES 08840928 T ES08840928 T ES 08840928T ES 2400107 T3 ES2400107 T3 ES 2400107T3
Authority
ES
Spain
Prior art keywords
ifn
compound
beta
arm
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08840928T
Other languages
English (en)
Spanish (es)
Inventor
Peter Hjelmstrom
Markus Imhof
George Feger
Nigel Jenkins
Philippe Dupraz
Christine Power
Laurent Magnenat
Philippe Chatellard
Renata Pankiewicz
Vincent Dechavanne
Gian Battista Bozzato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Application granted granted Critical
Publication of ES2400107T3 publication Critical patent/ES2400107T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08840928T 2007-10-22 2008-10-21 IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado Active ES2400107T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07118980 2007-10-22
EP07118980 2007-10-22
US714207P 2007-12-11 2007-12-11
US7142P 2007-12-11
PCT/EP2008/064224 WO2009053368A1 (en) 2007-10-22 2008-10-21 Single ifn-beta fused to a mutated igg fc fragment

Publications (1)

Publication Number Publication Date
ES2400107T3 true ES2400107T3 (es) 2013-04-05

Family

ID=39048918

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08840928T Active ES2400107T3 (es) 2007-10-22 2008-10-21 IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado

Country Status (6)

Country Link
EP (1) EP2203180B1 (enExample)
JP (1) JP5314033B2 (enExample)
AU (1) AU2008314697B2 (enExample)
ES (1) ES2400107T3 (enExample)
IL (1) IL204948A (enExample)
WO (1) WO2009053368A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071096B2 (en) 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CA2714296A1 (en) 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies
TWI544077B (zh) 2009-03-19 2016-08-01 中外製藥股份有限公司 Antibody constant region change body
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
WO2011101284A1 (en) * 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii fusion protein
EP2543730B1 (en) * 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
PT2591006T (pt) * 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
ES2929575T3 (es) * 2011-06-06 2022-11-30 Novo Nordisk As Anticuerpos terapéuticos
WO2013011062A2 (en) * 2011-07-18 2013-01-24 Novo Nordisk A/S Oscar antagonists
BR112014010257A2 (pt) 2011-10-31 2017-04-18 Chugai Pharmaceutical Co Ltd molécula de ligação ao antígeno tendo conjugação regulada entre cadeias pesadas e cadeias leves
ES2819217T3 (es) 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
KR20170017916A (ko) 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 면역 억제 기능을 갖는 세포에 대한 t 세포 리다이렉트 항원 결합 분자
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6805142B2 (ja) * 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
WO2017055582A1 (en) 2015-10-01 2017-04-06 Novo Nordisk A/S Protein conjugates
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
EP3431102A4 (en) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
CA3121699A1 (en) * 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
JP7359864B2 (ja) 2019-07-10 2023-10-11 中外製薬株式会社 クローディン６結合分子およびその使用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4294845A4 (en) * 2021-02-22 2026-01-07 Abdera Therapeutics Inc Immunoconjugates for targeted radioisotope therapy
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途
TW202611088A (zh) 2024-07-23 2026-03-16 美商雅博得樂醫療公司 5t4結合多肽及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
CA2491129A1 (en) * 2002-07-03 2004-01-15 Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7803910B2 (en) * 2005-01-24 2010-09-28 Merck Serono S.A. Soluble CD164 polypeptides
CN101184771A (zh) * 2005-05-26 2008-05-21 先灵公司 干扰素－IgG融合体

Also Published As

Publication number Publication date
JP5314033B2 (ja) 2013-10-16
JP2011500073A (ja) 2011-01-06
IL204948A (en) 2015-11-30
EP2203180B1 (en) 2012-11-21
WO2009053368A1 (en) 2009-04-30
AU2008314697B2 (en) 2013-08-29
EP2203180A1 (en) 2010-07-07
AU2008314697A1 (en) 2009-04-30
IL204948A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
AU2008314697B2 (en) Single IFN-beta fused to a mutated lgG Fc fragment
JP6329585B2 (ja) 単量体抗体Ｆｃ
TWI667255B (zh) 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
JP5781501B2 (ja) 改変されたＦｃＲｎ結合部位を有する抗体融合タンパク質
TWI667258B (zh) 因子ｖｉｉｉ與ｘｔｅｎ及范威爾邦德（ｖｏｎ ｗｉｌｌｅｂｒａｎｄ）因子蛋白質之複合物及其用途
KR102276157B1 (ko) 고글리코실화 인간 혈액응고인자 viii 융합 단백질 및 그 제조방법과 용도
ES2428894T3 (es) Inmunoglobulina glicosilada e inmunoadhesina que la comprende
CZ25697A3 (en) Novel compounds
CN105073781A (zh) 牛融合抗体
JP2015503349A5 (enExample)
JP2012532608A (ja) ＣＨ３ドメイン界面操作を通じた、安定でそして凝集しない抗体Ｆｃ分子の設計
KR102722304B1 (ko) Uti 융합 단백질
ES3014555T3 (en) Scfv-fc dimers that bind transforming growth factor-beta1 with high affinity, avidity and specificity
AU2020336980B2 (en) Antibody compositions and methods for treating hepatitis B virus infection
JP2021509590A (ja) ＩｇＥ Ｆｃ受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法
JP2023551667A (ja) 抗－インフルエンザ抗体及びその組合せ
CN117412989A (zh) 具有改进的特性的双功能分子的新支架
JP2023551666A (ja) Ａ型インフルエンザウイルスに対する抗体
HK1168607A (en) Antibody fusion proteins with modified fcrn binding sites
AU2015201449A1 (en) Carrier Immunoglobulins And Uses Thereof